John P O'Donnell

7PUBLICATIONS
14CO-AUTHORS
PharmacogenomicsMedical bacteriologyBacteriologyCheminformatics and quantitative structure-activity relationshipsEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 27, 2026
Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.

Alison Luckey, Kajal B Larson, Noha Rayad

|Mar 01, 2024
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii.

Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan

|Dec 13, 2023
n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex.

John O'Donnell, Angela Tanudra, April Chen

|Dec 13, 2023
In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex.

John O'Donnell, Angela Tanudra, April Chen

|Jul 14, 2020
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.

Thomas F Durand-Réville, Janelle Comita-Prevoir, Jing Zhang

|May 08, 2020
Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.

John O'Donnell, Angela Tanudra, April Chen

Pageof 2

Frequent Collaborators

4 joint publications

John P Mueller

2 joint publications

Alita A Miller

2 joint publications

Ruben Tommasi

1 joint publications

Thomas F Durand-Réville